Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06817720 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
A Phase 2 study of Chronic Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06817720 is a Phase 2 study of Chronic Myeloid Leukemia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 209-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06817720, a Phase 2 study of Chronic Myeloid Leukemia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.
Conditions Studied
Interventions
- DRUG olverembatinib
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2027-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06817720
The ClinicalTrials.gov registry entry for NCT06817720 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (76% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which olverembatinib is the first listed.
NCT06817720 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06817720 about?
NCT06817720 is a clinical study titled "Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase". To learn if olverembatinib can help to control newly diagnosed CML in the chronic phase.
What is the current status of trial NCT06817720?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-10-13. Estimated completion is 2027-03-07.
What conditions does trial NCT06817720 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia.
What interventions are being tested in trial NCT06817720?
The interventions under investigation include: olverembatinib (DRUG).
Who is sponsoring clinical trial NCT06817720?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06817720 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
RECRUITING · Phase 2
-
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
RECRUITING · Phase 2
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
ACTIVE NOT RECRUITING · Phase 2
-
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
COMPLETED · Phase 2
-
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.